Intellia Therapeutics Inc
$ 13.58
3.19%
24 Feb - close price
- Market Cap 1,524,322,000 USD
- Current Price $ 13.58
- High / Low $ 13.84 / 13.12
- Stock P/E N/A
- Book Value 6.46
- EPS -4.25
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.52 %
- 52 Week High 28.25
- 52 Week Low 5.90
About
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$23.86
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-20 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-11-09 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0 | -0.92 | -0.98 | -1.1 | -1.27 | -1.34 | -1.52 | -1.12 | -1.46 | -1.38 | -1.4 | -1.17 |
| Estimated EPS | -0.9631 | -1.01 | -1.03 | -1.2711 | -1.3164 | -1.38 | -1.23 | -1.38 | -1.45 | -1.5 | -1.32 | -1.4 |
| Surprise | 0.9631 | 0.09 | 0.05 | 0.1711 | 0.0464 | 0.04 | -0.29 | 0.26 | -0.01 | 0.12 | -0.08 | 0.23 |
| Surprise Percentage | 100% | 8.9109% | 4.8544% | 13.4608% | 3.5248% | 2.8986% | -23.5772% | 18.8406% | -0.6897% | 8% | -6.0606% | 16.4286% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.99 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NTLA
2026-02-23 17:10:35
Investors interested in Intellia Therapeutics Inc (NTLA) shares, but hesitant about the current market price of $12.71, can consider selling a January 2028 put at the $10 strike price. This strategy offers a potential 32% return on the $10 commitment, or a 16.8% annualized rate of return, by collecting a premium of $3.20 per share. The put seller would only acquire shares if NTLA's price drops below $10, resulting in a cost basis of $6.80 per share before commissions.
2026-02-22 21:42:53
UCL scientists have developed an investigational gene editing therapy for hereditary transthyretin (ATTR) amyloidosis, a debilitating genetic disorder. The therapy, which uses CRISPR/Cas9, aims to inactivate the harmful gene responsible for the condition. Early clinical trial results show a significant reduction in the harmful protein production, offering hope for a breakthrough in treating genetic disorders.
2026-02-21 12:15:00
Jupiter Asset Management Ltd. has invested $23.52 million in Intellia Therapeutics, Inc. by purchasing 1,361,849 shares in the third quarter, now owning about 1.27% of the company. Other institutional investors have also adjusted their holdings in Intellia Therapeutics, which is a clinical-stage biotechnology company focused on CRISPR/Cas9 genome editing therapies. Analysts currently have a "Hold" rating on NTLA with an average price target of $17.48, while company insiders have recently sold shares.
2026-02-20 22:26:31
Intellia Therapeutics (NTLA), a clinical-stage gene editing company with a market cap of $1.51 billion, is attracting investor interest due to an 82.95% potential upside. Despite currently operating at a loss with a negative P/E ratio, the company shows robust revenue growth of 51.30% and is actively investing in its promising pipeline through strategic collaborations. Analyst sentiment is mixed but leans positive, with a wide target price range suggesting significant long-term potential for risk-tolerant investors.
2026-02-19 16:55:24
Intellia Therapeutics (NTLA) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th. Analysts are forecasting a loss of ($0.99) per share on revenue of approximately $12.17 million. Company insiders, including CEO John M. Leonard and EVP Birgit C. Schultes, have recently sold shares, with institutional investors holding a significant portion of the stock.
2026-02-19 12:45:00
Intellia Therapeutics will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth-quarter and full-year 2025 financial results and business updates. The company, a leader in CRISPR-based gene editing, aims to revolutionize medicine for unmet medical needs. A webcast and phone access details are provided, with a replay available for 90 days.
